Evaluation of the Clinical Impact of Adjunctive L-carnitine Therapy in Critically Ill Hepatic Patients Admitted to Intensive Care Unit
- Hepatic
At a glance
- Phase
- Phase 4
- Study type
- Interventional
- Sponsor
- Beni-Suef University
- Enrolment target
- 58
- Started
- 15 June 2026
- Main results due
- December 2026
- Study sites
- 1
- Registry updated
- 23 September 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Age more than 18 years old * male or female with confirmed liver disease admitted to intensive care unit, including: * Acute-on-chronic liver failure (ACLF) * Hepatic encephalopathy * spontaneous bacterial peritonitis (SBP) * variceal bleeding * fulminant hepatitis * Hepatorenal syndrome * Ascites * Etc Exclusion Criteria: * Age of less than 18 years old * Pregnancy or Lactation * patients have seizure * patient on warfarin
What this study is about
In the sponsor’s own words, from the registry.
This study aims to evaluate the possible efficacy of l-carnitine in critically ill hepatic patients admitted to intensive care unit.
Study sites(1)
National liver institute
Shibīn al Kawm, Egypt
Recruiting
Showing 1 of 1 sites. 1 of the 1 site on this study is recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07642076. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me